IVAN ROSAS to Vital Capacity
This is a "connection" page, showing publications IVAN ROSAS has written about Vital Capacity.
Connection Strength
0.880
-
Broad Therapeutic Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2016 Jan 15; 193(2):112-3.
Score: 0.500
-
A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest. 2018 01; 153(1):94-104.
Score: 0.141
-
Development, Progression, and Mortality of Suspected Interstitial Lung Disease in COPDGene. Am J Respir Crit Care Med. 2024 Dec 15; 210(12):1453-1460.
Score: 0.058
-
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease. Rheumatology (Oxford). 2023 05 02; 62(5):1877-1886.
Score: 0.052
-
Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Lancet Respir Med. 2017 11; 5(11):857-868.
Score: 0.035
-
Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial. Chest. 2017 06; 151(6):1302-1310.
Score: 0.034
-
A comparison of visual and quantitative methods to identify interstitial lung abnormalities. BMC Pulm Med. 2015 Oct 29; 15:134.
Score: 0.031
-
Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J. 2015 Sep; 46(3):783-94.
Score: 0.030